Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone857-264-4280
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees54
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions
What is Rhythm Pharmaceuticals' stock symbol?
Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."
How were Rhythm Pharmaceuticals' earnings last quarter?
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) posted its earnings results on Friday, May, 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by $0.08. View Rhythm Pharmaceuticals' Earnings History.
When is Rhythm Pharmaceuticals' next earnings date?
What price target have analysts set for RYTM?
5 Wall Street analysts have issued 12 month price objectives for Rhythm Pharmaceuticals' shares. Their forecasts range from $34.00 to $43.00. On average, they anticipate Rhythm Pharmaceuticals' stock price to reach $39.40 in the next twelve months. This suggests a possible upside of 86.6% from the stock's current price. View Analyst Price Targets for Rhythm Pharmaceuticals.
What is the consensus analysts' recommendation for Rhythm Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rhythm Pharmaceuticals.
What are Wall Street analysts saying about Rhythm Pharmaceuticals stock?
Here are some recent quotes from research analysts about Rhythm Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA. " (5/17/2019)
- 2. Needham & Company LLC analysts commented, "Rhythm reported 1Q19 financial results today and we spoke w/ mgmt for an update. Top-line results from setmelanotide Phase 3 trials in POMC and LEPR are expected 3Q19. We continue to expect positive outcomes based on impressive Phase 2 data. Rhythm is still opening sites in the setmelanotide Phase 3 trial in pts w/ but mgmt reiterated guidance for completing enrollment in 2H19 and results in 2H20. The company is assessing 6-12 other rare genetic obesity disorders for potential inclusion in the ongoing Phase 2 basket trial. An update is expected later this yr. Mgmt also plans to share more data from GO-ID obesity DNA sequencing study and TEMPO rare genetic obesity registry later this yr. BUY." (5/5/2019)
- 3. Stifel Nicolaus analysts commented, "We update our model accordingly. Overall, our thesis remains unchanged and while we continue to model a high POS for setmelanotide as a treatment for rare genetic obesity disorders, we feel this is largely factored into the stock, and ultimately the lack of near-term catalysts and questions around the size of the commercial opportunity for POMC and LepR deficiency obesities keeps us on the sidelines for now. The company continues to make good progress in its setmelanotide Phase 3 programs and we think any incremental updates on the status of its TEMPO registry efforts to identify patients with genetic obesities, particularly ones which could be treated with setmelanotide, could prove to be positive catalysts if it looks like the prevalence of these disorders are greater than clinical epidemiology/literature has shown. We maintain our Hold rating and $36 target price." (11/11/2018)
Has Rhythm Pharmaceuticals been receiving favorable news coverage?
Media stories about RYTM stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Rhythm Pharmaceuticals earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an effect on the stock's share price in the next few days. View News Stories for Rhythm Pharmaceuticals.
Are investors shorting Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 1,560,500 shares, an increase of 9.3% from the April 30th total of 1,427,600 shares. Based on an average trading volume of 100,400 shares, the days-to-cover ratio is presently 15.5 days. Approximately 8.2% of the shares of the company are sold short. View Rhythm Pharmaceuticals' Current Options Chain.
Who are some of Rhythm Pharmaceuticals' key competitors?
Some companies that are related to Rhythm Pharmaceuticals include Agios Pharmaceuticals (AGIO), Arena Pharmaceuticals (ARNA), Amicus Therapeutics (FOLD), The Medicines (MDCO), Reata Pharmaceuticals (RETA), Arrowhead Pharmaceuticals (ARWR), PTC Therapeutics (PTCT), Intercept Pharmaceuticals (ICPT), Emergent Biosolutions (EBS), Akcea Therapeutics (AKCA), Ligand Pharmaceuticals (LGND), Myokardia (MYOK), Amneal Pharmaceuticals (AMRX), Insmed (INSM) and Zai Lab (ZLAB).
What other stocks do shareholders of Rhythm Pharmaceuticals own?
Who are Rhythm Pharmaceuticals' key executives?
Rhythm Pharmaceuticals' management team includes the folowing people:
- Dr. Keith Michael Gottesdiener, Pres, CEO & Director (Age 65)
- Mr. Hunter C. Smith, CFO & Treasurer (Age 50)
- Ms. Nithya Desikan, Chief Commercial Officer (Age 40)
- Mr. Leonardus H.T. van der Ploeg, Chief Scientific Officer (Age 64)
- Mr. Simon D. Kelner, Chief HR Officer (Age 46)
When did Rhythm Pharmaceuticals IPO?
(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.
Who are Rhythm Pharmaceuticals' major shareholders?
Rhythm Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (9.54%), TRV GP LLC (5.76%), FMR LLC (4.62%), Federated Investors Inc. PA (2.59%), TimesSquare Capital Management LLC (2.15%) and Alps Advisors Inc. (0.24%). Company insiders that own Rhythm Pharmaceuticals stock include Bros Advisors Lp Baker, David P Meeker, Der Ploeg Leonardus HT Van, James E Flynn, Keith Michael Gottesdiener, Orbimed Advisors Llc and SA Ipsen. View Institutional Ownership Trends for Rhythm Pharmaceuticals.
Which institutional investors are selling Rhythm Pharmaceuticals stock?
RYTM stock was sold by a variety of institutional investors in the last quarter, including TRV GP LLC, FMR LLC, TimesSquare Capital Management LLC, Emory University, Federated Investors Inc. PA and Metropolitan Life Insurance Co NY. Company insiders that have sold Rhythm Pharmaceuticals company stock in the last year include Der Ploeg Leonardus HT Van and Keith Michael Gottesdiener. View Insider Buying and Selling for Rhythm Pharmaceuticals.
Which institutional investors are buying Rhythm Pharmaceuticals stock?
RYTM stock was acquired by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Hamilton Lane Advisors LLC, Rice Hall James & Associates LLC, Janus Henderson Group PLC, Marshall Wace LLP, Tiff Advisory Services Inc., Alps Advisors Inc. and TD Asset Management Inc.. Company insiders that have bought Rhythm Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, David P Meeker, James E Flynn and SA Ipsen. View Insider Buying and Selling for Rhythm Pharmaceuticals.
How do I buy shares of Rhythm Pharmaceuticals?
Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rhythm Pharmaceuticals' stock price today?
One share of RYTM stock can currently be purchased for approximately $21.11.
How big of a company is Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals has a market capitalization of $726.86 million. The company earns $-74,060,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Rhythm Pharmaceuticals employs 54 workers across the globe.View Additional Information About Rhythm Pharmaceuticals.
What is Rhythm Pharmaceuticals' official website?
How can I contact Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals' mailing address is 500 BOYLSTON STREET 11TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]
MarketBeat Community Rating for Rhythm Pharmaceuticals (NASDAQ RYTM)
| Community Ranking: | | 2.6 out of 5 ( ) |
| Outperform Votes: | | 153 (Thanks for Voting!) |
| Underperform Votes: | | 146 (Thanks for Voting!) |
| Total Votes: | | 299 |
